Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148182 | 0.72 | MMP2 (0.41) | OPRM1LMNAALDH1A1CYP2C9BLM | |
| SCHEMBL15524924 | 0.72 | OPRM1 (0.38) | OPRM1HTR2ACACNA1FALDH1A1MAPT | |
| SCHEMBL28487408 | 0.70 | OPRM1 (0.33) | OPRM1HTR2ACACNA1FALDH1A1MAPT | |
| SCHEMBL1698175 | 0.69 | CA1 (0.37) | OPRM1OPRK1OPRL1CFTRGOPC | |
| SCHEMBL74066 | 0.69 | OPRM1 (0.36) | OPRM1ALDH1A1CYP2C9OPRK1OPRL1 | |
| SCHEMBL19915014 | 0.67 | OPRM1 (0.34) | OPRM1LMNAALDH1A1KCNH2MMP2 | |
| SCHEMBL5028816 | 0.67 | GAA (0.39) | OPRM1LMNAALDH1A1MAPTOPRL1 | |
| SCHEMBL7132657 | 0.67 | LMNA (0.33) | OPRM1LMNACYP2C9MAOBMAOA | |
| SCHEMBL2307390 | 0.67 | ALDH1A1 (0.50) | LMNAALDH1A1MAPT | |
| SCHEMBL28685313 | 0.67 | CYP2D6 (0.38) | OPRM1ALDH1A1KCNH2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058380-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-03-06 | — | — | US | claimed |
| EP-1417189-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-12-14 | — | — | EP | claimed |
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI (FR) | 2004-09-02 | — | — | US | claimed |
| EP-4644393-A1 | WRN INHIBITOR | Suzhou Puhe Biopharma Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025051129-A1 | ARYL HETEROCYCLIC SLC7A11 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024222677-A1 | WRN INHIBITOR | 苏州浦合医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024140714-A1 | WRN INHIBITOR | 苏州浦合医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024140597-A1 | WRN HELICASE INHIBITOR | 苏州浦合医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-112661913-B | Preparation method of functional polycarboxylic acid water reducer capable of resisting flocculating agent in machine-made sand | 江苏亚琛材料科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-112661913-A | Preparation method of functional polycarboxylic acid water reducer capable of resisting flocculating agent in machine-made sand | 江苏亚琛材料科技有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-112341727-A | Blue butyronitrile-simulated PVC gloves with super-high elasticity and production process thereof | 山东英科医疗制品有限公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-1777593-A | Acylaminothiazole derivatives, process for their preparation and their use as inhibitors of beta-amyloid peptide production | SANOFI AVENTIS (FR) | 2006-05-24 | — | — | CN | disclosed |
| US-20060052426-A1 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | US | disclosed |
| CN-1592746-A | LFA-1 antagonist compounds | GENENTECH INC (US) | 2005-03-09 | — | — | CN | disclosed |
| CN-1188407-C | Imidazole derivatives with inhabiting activity to transterasa and preparing method thereof | LG CHEMICAL LTD (KR) | 2005-02-09 | — | — | CN | disclosed |
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI (FR) | 2004-09-02 | — | — | US | disclosed |
| CN-1148348-C | 1-substituted-N-sulfinyl-2-aziridine methylenimine and its preparation and use | 中国科学院上海有机化学研究所 | 2004-05-05 | — | — | CN | disclosed |
| CN-1441806-A | Macrocyclic NS 3-serine protease inhibitors of hepatitis C virus comprising an N-ring P2 moiety | SCHERING CORP (US) | 2003-09-10 | — | — | CN | disclosed |
| CN-1308062-A | 1-substituted-N-sulfinyl-2-aziridine methylenimine and its preparation and use | SHANGHAI INST ORGANIC CHEM (CN) | 2001-08-15 | — | — | CN | disclosed |
| CN-1279680-A | Imidazole derivatives having farnesyl transferase inhibitory activity and process for producing the same | LG CHEMICAL LTD (KR) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058380-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PARK7, ACAT1, APP | OPRM1 2191/4885LMNA 3719/4885HTR2A 1415/4885 |
| US-20060052426-A1 | Acylaminothiazole derivatives, their preparation and their therapeutic use | CBR3, CBR1, NAT1 | OPRM1 439/4885LMNA 3259/4885HTR2A 3318/4885 |
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, CBR1 | OPRM1 161/4885LMNA 3198/4885HTR2A 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.